BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aikawa NE, Kupa LDVK, Medeiros-ribeiro AC, Saad CGS, Yuki EFN, Pasoto SG, Rojo PT, Pereira RMR, Shinjo SK, Sampaio-barros PD, Andrade DCO, Halpern ASR, Fuller R, Souza FHC, Guedes LKN, Assad APL, Moraes JCBD, Lopes MRU, Martins VADO, Betancourt L, Ribeiro CT, Sales LP, Bertoglio IM, Bonoldi VLN, Mello RLP, Balbi GGM, Sartori AMC, Antonangelo L, Silva CA, Bonfa E. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Ann Rheum Dis. [DOI: 10.1136/annrheumdis-2021-222096] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang Q, Ning J, Chen Y, Li B, Shi L, He T, Zhang F, Chen X, Zhai A, Wu C. The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults. Front Microbiol 2022;13. [DOI: 10.3389/fmicb.2022.1008420] [Reference Citation Analysis]
2 Pereira RM, Dagostin MA, Caparbo VF, Sales LP, Pasoto SG, Silva CA, Yuki EF, Saad CG, Medeiros-ribeiro AC, Kupa LV, Fusco SR, Martins VA, Martins CC, Barbas CV, Shinjo SK, Aikawa NE, Bonfa E. Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: immunogenicity, safety, antibody decay and the booster dose. Clinics 2022. [DOI: 10.1016/j.clinsp.2022.100150] [Reference Citation Analysis]
3 Habermann E, Gieselmann L, Tober-Lau P, Klotsche J, Albach FN, Ten Hagen A, Zernicke J, Ahmadov E, Arumahandi de Silva AN, Frommert LM, Kurth F, Sander LE, Burmester GR, Klein F, Biesen R. Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination. RMD Open 2022;8:e002639. [PMID: 36216410 DOI: 10.1136/rmdopen-2022-002639] [Reference Citation Analysis]
4 Belov BB, Muravyeva NV, Kulikov AN. Immunogenicity of Vaccines Against SARS-CoV-2 In Patients With Rheumatic Diseases. A&Ch 2022;67:70-80. [DOI: 10.37489/0235-2990-2022-67-5-6-70-80] [Reference Citation Analysis]
5 Boedecker-Lips SC, Claßen P, Kraus D, Weinmann-Menke J. Belimumab is not associated with COVID-19 mRNA vaccination failure in systemic lupus erythematosus. Rheumatology (Oxford) 2022:keac459. [PMID: 35972412 DOI: 10.1093/rheumatology/keac459] [Reference Citation Analysis]
6 Hoffmann-vold A, Distler O, Bruni C, Denton CP, de Vries-bouwstra J, Matucci Cerinic M, Vonk MC, Gabrielli A. Systemic sclerosis in the time of COVID-19. The Lancet Rheumatology 2022;4:e566-e575. [DOI: 10.1016/s2665-9913(22)00130-8] [Reference Citation Analysis]
7 Habermann E, Gieselmann L, Tober-lau P, Hagen AT, Albach FN, Zernicke J, Ahmadov E, de Silva ANA, Frommert LM, Klotsche J, Kurth F, Sander LE, Burmester G, Klein F, Biesen R. Impaired Neutralization of SARS-CoV-2 Including Omicron Variants after COVID-19 mRNA Booster Immunization under Methotrexate Therapy.. [DOI: 10.1101/2022.06.11.22276272] [Reference Citation Analysis]
8 Durán J, Burgos PI, Le Corre N, Ruiz Tagle C, Martinez-Valdebenito C, Castro M, Metcalfe V, Niemann P, Elvira Balcells M. Humoral immune-response to a SARS-CoV-2-BNT162b2 booster in inflammatory arthritis patients who received an inactivated virus vaccine. Ann Rheum Dis 2022:annrheumdis-2022-222189. [PMID: 35418480 DOI: 10.1136/annrheumdis-2022-222189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tanriover MD, Akova M. COVID-19 vaccine booster strategy: striving for best practice. The Lancet Global Health 2022. [DOI: 10.1016/s2214-109x(22)00204-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]